Systemic chemotherapy for advanced bladder cancer: Update and controversies

Journal of Clinical Oncology

Volumn 24, Issue 35, 2006, Pages 5545-5551

  Garcia, Jorge A ^a   Dreicer, Robert ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LAPATINIB; LONAFARNIB; METHOTREXATE; PACLITAXEL; PEMETREXED; SORAFENIB; SUNITINIB; TRASTUZUMAB; VINBLASTINE; VINFLUNINE; ANTINEOPLASTIC AGENT;

ANEMIA; BLADDER CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HUMAN; MUCOSA INFLAMMATION; NEUTROPENIA; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; ADJUVANT THERAPY; BLADDER TUMOR; RANDOMIZED CONTROLLED TRIAL; TRANSITIONAL CELL CARCINOMA;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; CISPLATIN; HUMANS; NEOADJUVANT THERAPY; RANDOMIZED CONTROLLED TRIALS; URINARY BLADDER NEOPLASMS;

EID: 34247363602     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.08.0564     Document Type: Review

References (65)

1. Jemal A, Siegel R, Ward E, et al: Cancer Statistics, 2006. CA Cancer J Clin 56:106-130, 2006
2. Ragahavan D: Chemotherapy and cystectomy for invasive transitional cell carcinoma of bladder. Urol Oncol 21:468-474, 2003
3. International Collaboration of Trialists on Behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group: Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. Lancet 354:533-540, 1999
4. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
5. Sternberg CN, Yagoda A, Scher H, et al: Preliminary results of MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of the urotheliutn. J Urol 133: 403-407, 1985
6. Sternberg CN, Yagoda A, Scher H, et al: Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989
7. Tannock I, Gospodarawiccz M, Connolly J, et al: MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989
8. Outan-Laroze A, Mahjoubi M, Droz JP, et al: MVAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced carcinoma of the bladder. Eur J Cancer 27:1690-1694, 1991
9. Igwa M, Ohkichi T, Ueda M, et al: Usefulness and limitations of methotrexate, vinblastine, doxorubicin, and cisplatin for the treatment of advanced urothelial cancer. J Urol 144:662-665, 1994
10. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate, and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract - A Northern California Oncology Group Study. J Clin Oncol 3:1463-1470, 1985
11. Loehrer Sr PJ, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, cisplatin, and doxorubicin in patients with metastatic Urothelial carcinoma: A cooperative group study. J Clin Oncol 10:1066-1073, 1992
12. Logothetis CJ, Dexeus FH, Finn I, et al: A retrospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990
13. Sternberg CN, de Mulder PHM, Schornagel JH, et al: Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J Clin Oncol 19:2638-2646, 2001
14. Hussain SA, James N: The systemic treatment of advanced and metastatic bladder cancer. Lancet Oncol 8:489-497, 2003
15. Von der Maase H, Andersen L, Crino L, et al: A phase II study of gemcitabine and cisplatin in patients with transitional cell carcinoma (TCC) of the urothelium. Proc Am Soc Clin Oncol 16, 1997 (abstr 1155)
16. Moore MJ, TAnnock I, Winquist E, et al: Gemcitabine (G) + Cisplatin: An active regimen in advanced transitional cell carcinoma (TCC) Proc Am Soc Clin Oncol 17, 1998 (abstr 1234)
17. Kauffman D, Raghavan D, Carducci M, et al: Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 18: 1921-1927, 2000
18. Von der Maase, Hansen SW, Roberts JT, et al: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multiinstitutional, multicenter, phase III study. J Clin Oncol 17:3068-3077, 2000
19. Von der Maase, Sengelow L, Roberts JT, et al: Long-term survival results of a randomized trial comparing gemcitabine and cisplatin with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602-4608, 2005
20. Dreicer R, Manola J, Roth BJ, et al: Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. Cancer 100:1639-1645, 2004
21. Bamias A, Aravantinos G, Deliveliotis C, et al: Docetaxel and cisplatin with granulocyte colony-stimulating factor (GCSF) versus MVAC with GCSF in advanced urothelial carcinoma: A multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. J Clin Oncol 22:220-228, 2004
22. Saxman S, Propert K, Einhorn L, et al: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study. J Clin Oncol 15:2564-2569, 1997
23. Barjorin DF, Dodd PM, Mazumdar M, et al: Long-term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 17:3173-3181, 1999
24. Schultz PK, Herr HW, Zhang ZF, et al: Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with 5-year follow- up. J Clin Oncol 12:1394-1401, 1994
25. Matos T, Cufer T, Cervek J, et al: Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach). Int J Radiat Oncol Biol Phys 46:403-409, 2000
26. Macneil HF, Hall RR, Neal DE, Roberts JT: Systemic chemotherapy for urothelial cancer in patients with ureteric obstruction. Br J Urol 67:169-172, 1991
27. Leibovitch I, Ben-Chaim J, Ramon J, et al. The significance of ureteral obstruction in invasive transitional cell carcinoma of the urinary bladder J Surg Oncol 52:31-35, 1993
28. Carteni G, Dogliotti L, Crucitta E, et al: Phase II randomized trial of gemcitabine plus cisplatin and gemcitabine plus carboplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelium. J Clin Oncol 22, 2003 (abstr 384)
29. Nogue-Aliguer M, Carles J, Arrivi A, et al: Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: An alternative therapy. Cancer 9:2180-2186, 2003
30. Olivares J, Hyman W, Senzer N, et al: A Phase II trial of gemcitabine and carboplatin in patients with transitional cell carcinoma of the urinary tract. J Clin Oncol 22:14, 2004 (abstr 4590)
31. Redman BG, Smith DC, Flaherty L, et al: Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 16:1844-1848, 1998
32. Burch PA, Richardson RL, Cha SS, et al: Phase II study of paclitaxel and cisplatin for advanced urothelial cancer. J Urol 164:1538-1542, 2000
33. Dreicer R, Manola J, Roth BJ, et al: Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study. J Clin Oncol 18:1058-1061, 2000
34. Small EJ, Lew D, Redman BG, et al: Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional cell carcinoma: The importance of survival as a clinical trial endpoint. J Clin Oncol 18:2537-2544, 2000
35. Vaughn DJ, Manola J, Dreicer R, et al: Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): A trial of the Eastern Cooperative Oncology Group. Cancer 95:1022-1027, 2002
36. Meluch AA, Greco FA, Burris HA, et al: Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Res Network. J Clin Oncol 10:3018-3024, 2001
37. Kauffman DS, Carducci MA, Kuzel TM, et al: A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 22:393-397, 2004
38. Paz-Ares L, Bezares S, Taberneo J, et al: Review of a promising new agent: Pemetrexed disodium. Cancer 97:2056-2063, 2003
39. Bellmunt J, Guillen V, Paz-Ares L, et al: Phase I-II study of paclitaxel, cisplatin ad gemcitabine in advanced transitional-cell carcinoma of the urothelium: Spanish Oncology Genitourinary Group. J Clin Oncol 18:3247-3255, 2000
40. Bajorin DF, McCaffrey JA, Dodd PM, et al: Ifosfamide, paclitaxel and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules. Cancer 88:1671-1678, 2000
41. Edelman MJ, Meyers FJ, Miller TR, et al: Phase I/II study of paclitaxel, carboplatin and methotrexate in advanced transitional cell carcinoma: A well-tolerated regimen with activity independent for p53 mutation. Urology 55:521-525, 2000
42. Hussain M, Vaishampayan U, Du W, et al: Combination paclitaxel, carboplatin, and gemcitabine are an active treatment for advanced urothelial cancer. J Clin Oncol 19:2527-2533, 2001
43. Bellmunt J, Hussain M, Dinney CP: Novel approaches with targeted therapies in bladder cancer: Therapy of bladder cancer by blockade of epidermal growth factor receptor family. Crit Rev Oncol Hematol 46:s85-104, 2003 (suppl)
44. Dominguez-Escrig JL, Kelly JD, Neal DE, et al: Evaluation and therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res 14:4874-4884, 2004
45. Phillips G, Halabi S, Sanford D, et al: Phase II trial of cisplatin (C), fixed-dose gemcitabine (G), and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALB 90102. J Clin Oncol 22, 2004 (abstr 4540)
46. Phillips G, Sanford D, Halabi S, et al: Phase II study of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial carcinoma (UC): Analysis of the second cohort of CALGB 90102. J Clin Oncol 23, 2005 (abstr 4578)
47. Jimenez R, Hussain M, Bianco FJ, et al: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder. Clin Cancer Res 7:2440-2447, 2001
48. Hussain M, Petrylak D, Dunn R, et al: Trastuzumab (T), Paclitaxel (P), Carboplatin (C), and gemcitabine (G) in advanced HER-2 positive urothelial carcinoma: Results of a multicenter phase II NCI trial. J Clin Oncol 23, 2005 (abstr 4507)
49. Du Z, Hou S: The anti-angiogenic activity of human endostatin inhibits bladder cancer growth and its mechanism. J Urol 70:2000-2003, 2003
50. Inoue K, Chikazawa M, Fukata S, et al: Administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin Cancer Res 8:2389-2398, 2002
51. Herr HW, Donat SM, Barjorin DF, et al: Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 165: 811-814, 2001
52. Witte R, Elson P, Bono B, et al: Eastern Cooperative Group Phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. J Clin Oncol 15:589-593, 1997
53. Krege S, Rembrink V, Borgermann C, et al: Docetaxel and Ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: A phase II study. J Urol 165:67-71, 2001
54. Pagliaro LC, Millikan RE, Tu S, et al: Cisplatin, gemcitabine, and ifosfamide as weekly therapy: A feasibility and phase II study of salvage treatment for advanced transitional cell carcinoma. J Clin Oncol 20:2965-2970, 2002
55. Tu SM, Hossan E, Amato R, et al: Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies. J Urol 154:1719-1722, 1995
56. Sweeney CJ, Williams SD, Finch DE, et al: A phase II study of paclitaxel and ifosfamide for patients with advanced refractory carcinoma of the urothelium. Cancer 86:514-518, 1999
57. Vaughn DJ, Broome CM, Hussain M, et al: Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 20:937-940, 2002
58. McCaffrey JA, Hilton S, Mazumdar C, et al: Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 15:1853-1857, 1997
59. Culine S, Theodore C, De Santis M, et al: A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br J Cancer 10:1395-1401, 2006
60. Roth BJ, Dreicer R, Einhorn LH, et al: Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12:2264-2270, 1994
61. Dreicer R, Gustin Dm, See WA, et al: Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy. J Urol 156:1606-1608, 1996
62. Dreicer R, Li S, Manola J, et al: Phase II trial of epothilone B analogue BMS-247550 in advanced carcinoma of the urothelium (E3800): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 24, 2006 (abstr 4543)
63. Sridhar S, Stadler W, Lee D, et al: Phase II study of Bortezomib in advanced of metastatic urothelial cancer: A trial of the Princess Margaret Hospital (PMH) phase II consortium. J Clin Oncol 23, 2005 (abstr 4677)
64. Theodore C, Geofrois L, Vermorken JB, et al: Multicenter EORTC study 16997: Feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer 8:1150-1157, 2005
65. Wulfing C, Machiels J, Richel D, et al: A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract. J Clin Oncol 23, 2005 (abstr 4594)